Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 2;29(5):337.e1–337.e5. doi: 10.1016/j.jtct.2023.01.025

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

(A) Anti-S IgG titers, in nAEB, in all recipients (n = 53) at 1, 3, and 6 months post-transplantation. The arrow indicates the approximate time of vaccination post-transplantation (∼3 months). (B) Anti-S IgG titers were analyzed at 1 month post-transplantation by immunologic status (D, donor; R, recipient; 0, no prior SARS-CoV-2 vaccination or infection before transplantation; 1, prior SARS-CoV-2 vaccination and/or infection before transplantation) for D0R0 (n = 14) and D1R1 (n = 14). The median titer was significantly higher for the D1R1 group compared with the D0R0 group (P = .008). (C) The anti-S IgG titers for recipients who were vaccinated between 3 and 6 months post-transplantation are represented by COVID-19 immunologic status, D0R0 (n = 7) or D1R1 (n = 2). Anti-S titers are shown at 6 months post-transplantation. No significant difference is observed between the D0R0 and D1R1 groups (P = .5). Values are median and IQR, and the dotted line at 1.07 nAEB represents the assay cutoff.